As in other neuropathic pain models, pharmacological inhibition of CRMP2 SUMOylation leads to decreased Nav1.7 currents through clathrin-mediated internalization of Nav1.7, thereby restoring mechanical sensitivity [128]. Here, SCN9A is linked to neuropathic pain.